{
    "organizations": [],
    "uuid": "3a5d0c6eb9c5666ad5d149c98a1000b44d414dd6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-shenzhen-neptunus-bioengineering-u/brief-shenzhen-neptunus-bioengineering-unit-passes-fda-approval-for-new-drug-clinical-trial-idUSL4N1PH31Z",
    "ord_in_thread": 0,
    "title": "BRIEF-Shenzhen Neptunus Bioengineering unit passes FDA approval for new drug clinical trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 22(Reuters) - Shenzhen Neptunus Bioengineering Co Ltd :\n* Says its wholly owned pharma tech unit received FDA approval for anti-tumor new drug clinical trail from U.S Food and Drug Administration\n* The unit will be able to conduct clinical trial of anti-tumor new drug in the United States after receiving the FDA approval\nSource text in Chinese: goo.gl/Ucdtfz\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-01-22T16:17:00.000+02:00",
    "crawled": "2018-01-23T17:51:30.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "shenzhen",
        "neptunus",
        "bioengineering",
        "co",
        "ltd",
        "say",
        "wholly",
        "owned",
        "pharma",
        "tech",
        "unit",
        "received",
        "fda",
        "approval",
        "new",
        "drug",
        "clinical",
        "trail",
        "food",
        "drug",
        "administration",
        "unit",
        "able",
        "conduct",
        "clinical",
        "trial",
        "new",
        "drug",
        "united",
        "state",
        "receiving",
        "fda",
        "approval",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}